A Universal Therapeutic Vaccine Leveraging Autologous Pre-Existing Immunity to Eliminate in Situ Uniformly Engineered Heterogeneous Tumor Cells

© 2025 Wiley‐VCH GmbH.

Détails bibliographiques
Publié dans:Advanced materials (Deerfield Beach, Fla.). - 1998. - 37(2025), 9 vom: 21. März, Seite e2412430
Auteur principal: Wu, Fuhua (Auteur)
Autres auteurs: Guo, Zhaofei, Yang, Jialiang, Ou, Yangsen, Xie, Xiejin, Liao, Hu, Guo, Chenqi, Zhan, Yuxi, Wu, Haiping, Hu, Rui, Xu, Yanhua, Tang, Xue, Wang, Haolin, Ye, Lin, He, Penghui, He, Chunting, Huang, Lu, Luo, Shuang, Sun, Xun, Yang, Zhenglin
Format: Article en ligne
Langue:English
Publié: 2025
Accès à la collection:Advanced materials (Deerfield Beach, Fla.)
Sujets:Journal Article adeno‐associated virus (AAV) pre‐existing immunity thermoresponsive injectable hydrogel tumor cells engineering universal tumor vaccine Cancer Vaccines Spike Glycoprotein, Coronavirus spike protein, SARS-CoV-2